Armata Pharmaceuticals promotes David House to CFO, effective July 17, 2026

Armata Pharmaceuticals, Inc.

David House appointed CFO; previously SVP Finance and principal financial officer since Aug 2024.
Base salary $371,315; target bonus 50% of base; annual equity award target $300,000.
Severance: 12 months base salary on involuntary termination without cause or for good reason.
Change-in-control acceleration: full vesting of time-based equity if termination within 1 month before or 12 months after CIC.
Also amended Pierre Kyme's employment agreement to conform change-in-control definition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.